MedTrace Logo

Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy

NCT00740142 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2020-09-04

No results posted yet for this study

Summary

Hypothesis: Is the combination of oral L-ornithine-L-aspartate and lactulose more efficacious than oral lactulose alone in treatment of hepatic encephalopathy? Study design; Randomized, double-blinded, placebo controlled trial

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

L-ornithine-L-aspartate and lactulose

L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days

DRUG

placebo and lactulose

placebo 3 times a day for 7 days

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Siwaporn Chainuvati, MD · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-08-31
Completion
2011-10-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740142 on ClinicalTrials.gov